Fennec Pharmaceuticals Inc (FENC) Stock Analysis
Fennec Pharmaceuticals Inc (FENC) is a publicly traded company in the HEALTHCARE sector. It trades at $9.88, carries a market capitalization of $343.20M. This page summarizes the public market data, fundamentals, and frequently asked questions for FENC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.
Sector: HEALTHCARE - BIOTECHNOLOGY
Exchange: NASDAQ
Key Metrics
- Price: $9.88
- Market Cap: $343.20M
- EPS: $-0.29
- 52-Week High: $10.45
- 52-Week Low: $5.65
Market Sentiment
Fennec Pharmaceuticals Inc currently has a Neutral sentiment score of 0.07.
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Research Triangle Park, North Carolina, dedicated to developing pioneering treatments for cancer, especially among pediatric patients. The company's lead product candidate, Pedmark, targets chemotherapy-induced ototoxicity in children, representing a vital innovation in oncology care. With a strong focus on enhancing patient quality of life, Fennec is well-positioned to make significant advancements in the oncology la...
GNG Research Analysis
GNG Research scores Fennec Pharmaceuticals Inc (FENC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for FENC.
Frequently Asked Questions
Does FENC pay dividends?
Fennec Pharmaceuticals Inc (FENC) does not currently pay a regular dividend.
What is FENC's market cap?
Fennec Pharmaceuticals Inc (FENC) has a market capitalization of $343.20M with a current stock price of $9.88.